CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  1    
PROTOCOL CY 50 22 
 
A PHASE 2, MULTI -CENTER, DOUBLE -BLIND , RANDOMIZED, DOSE -RANGING, 
PLACEBO -CONTROLLED  STUDY TO EVALUATE THE EFFICACY, SAFETY, AND 
TOLERABILITY OF CK -2127107 IN PATIENTS  WITH 
AMYOTROPHIC LATERAL  SCLEROSIS (ALS )  
 
Product:      CK-[ADDRESS_438795] Number:   2018-000586-37  
 
Sponsor:      Cytokinetics Inc.  
       [ADDRESS_438796] 
South San Francisco, [LOCATION_004] [ZIP_CODE] 
 
Original Protocol:   6 March  2017 
Amendment 01:    23 Ma rch 2017 
Amendment 01.1:  16 June 2017 (CANADA) 
Amendment 02:  [ADDRESS_438797] 2017 
Amendment 02. 1: 18 February 2018 (EUROPE) 
Amendment 03:  18 April  2018 
 
 
CONFIDENTIAL  
DO NOT COPY OR REPRODUCE  
WITHOUT CONSENT OF CYTOKINETICS, INC.    
Sponsor (Medical Monitor) Signature:___________________________________________ 
 
Lead Investigator Signatu re:___________________________________________________ 

CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438798] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................................10  
1. INTRODUCTION  ......................................................................................................13  
1.1. Background .................................................................................................................13  
1.2. Overview of CK -2127107 Nonclinical Studies  ..........................................................13  
1.3. Overview of CK -2127107 Clinical Studies ................................................................14  
2. STUDY OBJECTIVES  ..............................................................................................17  
2.1. Primary Objective  .......................................................................................................17  
2.1.1.  Primary Efficacy Endpoint .........................................................................................17  
2.2. Secondary Objectives  .................................................................................................17  
2.2.1.  Secondary Endpoints ..................................................................................................17  
2.3. Exploratory Objectives ...............................................................................................17  
2.3.1.  Exploratory Endpoints ................................................................................................18  
2.4. Pharmacokinetic / Pharmacodynamic Objective  ........................................................[ADDRESS_438799] Dosing Day (Day 1) ...........................................................................................25  
5.3. Week 2 Visit  ...............................................................................................................26  
5.4. Week 4 Visit  ...............................................................................................................27  
5.5. Week 8 Visit  ...............................................................................................................28  
5.6. Week 12 Visit .............................................................................................................29  
5.7. Follow- Up Visit  ..........................................................................................................29  
5.8. Early Termination Visit ..............................................................................................30  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438800] Screen (BDI -Fast Screen)  ......................................33  
5.13.8.  Falls Assessment  .........................................................................................................33  
5.13.9.  Ashworth Scale ...........................................................................................................33  
5.14.  Clinical and Pharmacodynamic Outcome Measures  ..................................................33  
5.14.1.  Pulmonary Function Assessment ................................................................................33  
5.14.2.  Hand -Held Dynamometry  ..........................................................................................34  
5.14.3.  ALSFRS -R ..................................................................................................................34  
5.14.4.  Voice Recording  .........................................................................................................34  
5.14.5.  Fine Motor Assessments (Handwriting and Figure Tracing) .....................................[ADDRESS_438801] .......................................................................37  
6.2. Dose Administration (CK -2127107 or Placebo) ........................................................37  
6.3. Dosing Diary  ...............................................................................................................37  
6.4. Randomization Schedule and Removal of Blind ........................................................37  
6.5. Study Drug Accountability and Disposal ...................................................................38  
7. ADVERSE EVENTS ..................................................................................................39  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  4   7.1. Definitions  ..................................................................................................................39  
7.1.1.  Adverse Event  .............................................................................................................39  
7.1.2.  Serious Adverse Event ................................................................................................40  
7.2. Collection of AEs/SAEs  .............................................................................................41  
7.3. Recording and Reporting of AEs/SAEs .....................................................................[ADDRESS_438802]- Study AEs/SAEs  .................................................................................................44  
7.7. Pregnancy  ...................................................................................................................44  
8. STATISTICAL METHODS  .......................................................................................45  
8.1. General Considerations ...............................................................................................45  
8.1.1.  General Approach  .......................................................................................................45  
8.1.2.  Sample Size and Randomization ................................................................................45  
8.2. Analysis Sets  ...............................................................................................................45  
8.2.1.  Full Analysis Set (FAS)  ..............................................................................................45  
8.2.2.  Safety Analysis Set (SAS)  ..........................................................................................45  
8.2.3.  Pharmacokinetics Analysis Set (PKS)  ........................................................................45  
8.3. Endpoints ....................................................................................................................46  
8.3.1.  Efficacy Endpoints ......................................................................................................46  
[IP_ADDRESS].  Primary Efficacy Endpoint .........................................................................................46  
[IP_ADDRESS].  Secondary Efficacy Endpoints ....................................................................................46  
[IP_ADDRESS].  Exploratory Efficacy Endpoints .................................................................................46  
8.3.2.  Safety  Endpoints .........................................................................................................46  
8.3.3.  Pharmacokinetic Measurements  .................................................................................47  
8.4. Statistical Analysis  ......................................................................................................47  
8.4.1.  Patient Disposition  ......................................................................................................47  
8.4.2.  Demographics and Other Baseline Characteristics  .....................................................47  
8.4.3.  Prior and Concomitant Medications ...........................................................................47  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  5   8.4.4.  Efficacy Analysis  ........................................................................................................47  
[IP_ADDRESS].  Primary Efficacy Analysis  ..........................................................................................47  
[IP_ADDRESS].  Secondary Efficacy Analysis  ......................................................................................47  
[IP_ADDRESS].  Exploratory Efficacy Analysis  ....................................................................................48  
[IP_ADDRESS].  Multiplicity  .................................................................................................................48  
8.4.5.  Safety Analysis  ...........................................................................................................48  
[IP_ADDRESS].  Study Drug Exposure ..................................................................................................48  
[IP_ADDRESS].  Adverse Event  .............................................................................................................48  
[IP_ADDRESS].  Serious Adverse Event ................................................................................................48  
[IP_ADDRESS].  Clinical Laboratory Parameters  ..................................................................................48  
[IP_ADDRESS].  Vital Signs  ..................................................................................................................49  
[IP_ADDRESS].  ECGs  ...........................................................................................................................49  
[IP_ADDRESS].  Physical and Neurological Examinations  ...................................................................49  
[IP_ADDRESS].  Ashworth Score ..........................................................................................................49  
[IP_ADDRESS].  Falls Assessments  .......................................................................................................49  
[IP_ADDRESS].  Beck Depression Inventory -Fast Screen  .....................................................................[ADDRESS_438803]/Research Ethics Board/Ethics Committee  ......................51  
9.6. Informed Consent .......................................................................................................52  
9.7. Records  .......................................................................................................................52  
9.8. Reference to Good Clinical Practices (GCP)  ..............................................................52  
10. REFERENCES  ...........................................................................................................53  
APPENDIX A.  SCHEDULE OF EVENTS  ................................................................................54  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  6   APPENDIX B.  MEDICATIONS AND FOODS THAT INHIBIT OR IN DUCE 
CYP3A4 OR ARE OCT1/OCT2 SUBSTRATES  ......................................................55  
APPENDIX C.  LIVER SAFETY MONITOR ING AND ASSESSMENT .................................56  
APPEN DIX D. CLINICAL LABORATORY EVALUATIONS  ...............................................59  
 
  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438804] OF TABLES  
Table 1:  CY 5022 Randomized, Double-Blind Treatment Groups ..........................................19  
Table 2:  Visit Windows  ............................................................................................................31  
Table 3:  Pharmacokinetic (PK) Samples  ..................................................................................32  
Table 4:  Study Drug  ..................................................................................................................37  
Table 5:  MedDRA Preferred Terms  .........................................................................................[ADDRESS_438805] OF FIGURES  
Figure  1: Patient Visit Diagram  .................................................................................................20  
Figure  2: CY 5013: Increases in Force during Nerve Stimulation in Healthy 
Volunteers ...................................................................................................................21  
 
 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438806] 
South San Francisco, [LOCATION_004], [ZIP_CODE] (650) 624- 3000 (Main Telephone)  
([PHONE_7282] (Main Facsimile) 
 
Sponsor’s Study Contact [CONTACT_352509], Clinical Operations  
Cytokinetics, Inc. 
[EMAIL_6754]  
(650) 624- 3017 (Office Telephone)  
(650) 291- 5533 (Mobile Telephone)  
([PHONE_7283] (Office Fac simile)  
 
 Sponsor’s Medical Monitor   Stacy Rudnicki, MD 
Senior  Medical  Director, Clinical Research , Neurology 
Cytokinetics, Inc. 
srudnicki @cytokinetics.com  
([PHONE_7284] (Office T elephone) 
([PHONE_7285] (Mobile Telephone)  
 
Lead Investigator  Jeremy Shefner, MD, PhD  
Professor & Chair of Neurology 
Barrow Neurological  Institute  
[EMAIL_6755] ([PHONE_7286] (Mobile Telephone) 
 
Study Site  Multi- Center  
 
 
 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  9   INVESTIGATOR PROTOCOL AGREEMENT P AGE  
 
I agree:  
• To assume responsibility for the proper conduct of the study at this site. 
• To conduct the study in compliance with this protocol, any future amendments, and 
with any other study conduct procedures provided by [CONTACT_352510]. 
• Not to amend the protocol without agreement, prior review, and written approval 
from the Institutional Review Boar d (IRB) /Ethics Committee (EC)  except where 
necessary to eliminate an immediate hazard to the patients.  
• That I am thoroughly familiar with the appropriate use of the investigational 
product(s), as described in this protocol and any other information provided by [CONTACT_352511], but not limited to, the following: the current Investigator’s 
Brochure (IB) or equivalent document. 
• That I am aware of, and will comply with, “Good Clinical Practices” (GCP) and all applicable regulatory requirements.  
• To ensure that all persons a ssisting me with the study are adequately informed about 
the Cytokinetics investigational product(s) and of their study- related duties and 
functions as described in the protocol. 
• That I have been informed that certain regulatory authorities require the Sponsor to 
obtain and supply, as necessary, details about the Investigator’s ownership interest in 
the Sponsor or the investigational product, and more generally about his/her financial 
ties with the Sponsor. Cytokinetics will use and disclose the information  solely for the 
purpose of complying with regulatory requirements. 
Hence I:  
• Agree to supply Cytokinetics with any necessary information regarding ownership 
interest and financial ties (including those of my spouse and dependent children); 
• Agree to promptly update this information if any relevant changes occur during the course of the study and for one year following completion of the study; and  
• Agree that Cytokinetics may disclose any information it has about such ownership interests and fi nancial ties to regulatory authorities.  
 
 
Investigator Name:  ______________________________________________________ 
 
Investigator Signature: ________________________________  Date: ________________  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438807] Term  Explanation  
AE adverse event  
ALP  alkaline phosphatase 
ALSAQ -5 ALS Assessment Questionnaire S hort Form 
ALS  amyotrophic lateral sclerosis  
ALSFRS -R ALS Functional Rating Scale - Revised  
ALT  alanine aminotransferase (alanine transaminase)  
API [INVESTIGATOR_352477] (aspartate transaminase)  
AT aminotransferase  
AUC  area under the plasma concentration -time curve  
BDI Beck Depression Inventory 
BMI  body mass index 
CBC complete blood count  
CFR Code of Federal Regulations 
CKD- EPI [INVESTIGATOR_31136]/F  clearance divided by [CONTACT_352512]-dose plasma concentration  
CTCAE  Common Terminology Criteria for Adverse Events  
CV coefficient of var iation  
CYP  Cytochrome P450 
DMC  Data Monitoring Committee  
EC Ethics Committee  
ECG  electrocardiogram  
eCRF  electronic case report form  
eGFR  estimated glomerular filtration rate  
FAS full analysis set  
FDA Food and Drug Administration 
GCP  Good Clinical Practices  
HHD  hand-held dynamometry 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438808] Term  Explanation  
IB Investigator’s Brochure  
IC50 half maximal inhibitory concentration  
ICF  informed consent form  
ICH International Conference on Harmonisation 
INR international normalized ratio 
IRB Institutional Review Board  
IV intravenous 
IWRS  interactive web r esponse system  
LFT liver function tests  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  mixed model for repeated measures  
OCT  organic cation transporter  
PD  pharmacodynamic (s) 
PK  pharmacokinetic(s)  
PKS pharmacokinetics analysis set  
PT preferred term  
QTc corrected QT interval  
RAC Accumulation ratio 
REB Research Ethics Board 
SAE  serious adverse event  
SAS safety analysis set  
SDD spray dried dispersion  
SOC  system organ class  
SVC  slow vital capacity  
t½  apparent plasma terminal elimination half -life 
TBL  total bilirubin  
TDD  total daily dose 
TEAE  treatment emergent adverse event  
tmax  time where maximum concentration is reached  
TSH  thyroid stimulating hormone  
UA  urinalysis  
ULN upper limit of normal 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438809] Term  Explanation  
V/F volume of distribution divided by [CONTACT_352513] 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438810] skeletal muscle troponin complex, a 
sarcomere-directed therapy intended to improve skeletal muscle function in conditions associated 
with muscle weakness and/or fatigue. CK-[ADDRESS_438811] skeletal muscle fibers.  It is expected that CK -2127107 may provide benefit to 
patients with a wide variety of disorders characterized by [CONTACT_352514]/or fatigue.  
ALS is a disease of the nerve cells in the brain and spi[INVESTIGATOR_352478]. In ALS, progressive death of motor neurons leads to denervation of skeletal muscles. 
Surviving motor units attempt to compensate for dying ones by [CONTACT_352515] 
(a process called sprouting) but are only partially successful ( Kiernan, Vucic et al. 2011) . Over 
time, progressive denervation and its consequent skeletal muscle atrophy lead to weakness, 
fatigue, and eventually complete paralysis and death, primarily from respi[INVESTIGATOR_11800]. 
No curative therapi[INVESTIGATOR_352479]. Rilutek
® (riluzole, [COMPANY_011]-Aventis U.S. LLC) is the first 
medication  approved for the treatment of ALS, and has a modest benefit on survival ( Lacomblez, 
Bensimon et al. 1996). Two interventions that contribute greatly to the overall welfare and 
survival of ALS patients are the use of enteral feeding and ventilatory support. 
Radicava (edaravone) was recently approved to treat patients with ALS  in the [LOCATION_002] in 
May 2017. The efficacy of Radicava was demonstrated in a 6-month clinical trial conducted in 
Japan  wherein 137 participants were randomized to receive edaravone or placebo. At Week 24, 
individuals receiving edaravone declined less on a clinical assessment of daily functioning 
compared to those receiving a placebo ( Writing Group on behalf of the Edaravone (MCI-186) 
ALS 19 Study Group. 2017). 
To date, there are no available treatments that slow the decline of  skeletal muscle function , and 
in particular , slow the decline of respi[INVESTIGATOR_4806]. This clinical protocol is a double-blind, 
randomized, dose- ranging, placebo -controlled study to evaluate the efficacy, safety, and 
tolerability of CK -2127107 in patients with ALS. 
1.2. Overview of CK-2127107  Nonclinical Studies  
CK-2127107 was evaluated in a series of nonclinical safety studies in rat  and monkey, including 
single - and repeat -dose (28 days and 13 weeks) toxicity studies, safety pharmacology studies, 
and a core battery of genotoxicity tests . CK -2127107 was formulated from a spray dried 
dispersion (SDD), which is a stabilized amorphous form of CK-2127107, to increase its 
absorption. 
The toxicology studies conducted in rat and monkey with CK-2127107 demonstrated an 
acceptable safety profile, and support ed Phase 1 clinical trials in healthy volunteers. Based on in 
vitro metabolism studies, the monkey w as selected as the non -rodent toxicology species since the 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438812] level  for CK-2127107 was 600 mg/kg/day, the highest dose level 
evaluated, in both rats and monkeys. 
The core battery of s afety pharmacology studies conducted with CK -[ADDRESS_438813] . 
CK-2127106 was equivocal in an in vitro cytogenetic assay conducted in human peripheral 
blood lymphocytes; in this assay, a statistically significant increase in the incidence of aberrant cells, compared to the vehicle control, was noted only at the highest CK -2127106 concentration 
evaluated (386 µg/mL) in the 21-hour regime. 
Additional information concerning the pharmacology, pharmaco kinetics ( PK), and toxicology of 
CK-2127107 is available in the Investigator’s Brochure  (IB) . 
1.3. Overview of CK-2127107  Clinical Studies  
Phase 1 Studies  
CK-2127107 has been evaluated in five Phase 1 studies. 
In a “first in human” study conducted in 35 healthy men (Study CY 5011), single oral doses of a 
SDD suspension ( CK-[ADDRESS_438814] cro ssover, single dose PK/pharmacodynamic (PD) study (Study CY  5013) performed 
with placebo, 300 mg, 1000 mg and 3000 mg of the CK -2127107 SDD suspension demonstrated 
a dose- and concentration-dependent increase in the force- frequency relationship of the tibialis 
anterior muscle with transcutaneous electric stimula tion of the deep fibul ar nerve.  
Another study in 25 healthy men (Study CY 5014) was conducted to evaluate the relative oral 
bioavailability of  a suspension of the crystalline form of  CK-2127107, CK-2127107 active 
pharmaceutical ingredient ( API), to the CK-[ADDRESS_438815] of the tablet w as also evaluated in Study CY 5015. 
The terminal half -life ( t½) of CK-2127107 was  generally around 12 hours with a time to 
maximum concentration (t max) of 2 -3 hours. The increase in exposure was  largely dose-
proportional although exposure was more variable at doses ≥3000 mg. There were no observed 
differences in PK parameters between young and elderly subjects but mean exposure was 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438816] was demonstrated with 2.6- and 1.6-fold 
increases in C max and AUC ∞, respectivel y, following administration of the tablet formulation 
(500 mg as 2 x 250 mg tablets) with a high fat meal. 
Exposure (C max and AUC) to the inactive metabolite, CK -2127106, was higher after multiple 
doses of CK-2127107 compared to single doses. The geometric mean half -life of CK -2127106 
ranged from 25.4 to 39.3 hours. Maximum concentrations (C max) and area under the 
concentration -time curve (AUC) values increased somewhat greater than dose-proportionally 
following multiple dosing.  
CK-2127107 was well tolerated at all dose levels with no serious adverse events (SAEs) or 
discontinuations due to an adverse event (AE). The most common (≥5%) AEs observed with 
CK-2127107 vs. placebo were dizziness, headache , nausea, and diarrhea. Dizziness , headache, 
and nausea appeared to be dose-related and their incidence increased at doses of 2250 mg and 
above . None of the AEs were classified as severe. Four subjects in the multiple dose study (one 
treated with placebo and three treated with CK -2127107 500 mg) had an AE  of increased alanine 
aminotransferase (ALT)/hepatic enzymes; an additional three subjects (all treated with CK-2127107 500 mg) had at least one elevated liver enzyme during treatment with study drug 
that were not reported as an AE. Of these seven subjects , some of whom also had modest 
bilirubin elevations, none had values that met Hy’s Law criteria. Other laboratory tests remained normal and consistent with baseline values following dosing with the exception of elevated serum creatinine values in most subj ects treated with CK -2127107. This was observed 
consistently across all studies. CK-2127107 has been demonstrated to inhibit organic cation transporter ( OCT ) 2, a mediator of renal tubular secretion of creatinine in the human kidney, 
with a half maximal in hibitory concentration ( IC
50) of 2.[ADDRESS_438817] likely reason for these generally small and reversible increases in serum creatinine during treatment with CK -2127107; inhibition 
of renal tubular secretion has also been observed with other drugs, such as cimetidine 
(Ducharme, Smythe et al. 1993). It is noted that a similar increase in creatinine has been 
observed in toxicology studies of CK-2127107 in monkey. In the 13-week monkey toxicology 
study, creatinine values returned to baseline after completion of dosing and there were no 
abnormalities in kidney histopathology noted, providing further support that this finding is not a 
reflection of renal toxicity.  
Additional information on the Phase 1 clinical program can be found in the IB. 
Ongoing Studies  
There are 3 ongoing stud ies with CK -2127107. 
3318- CL-3001 ( [STUDY_ID_REMOVED]) is a Phase 1b, double-blind, randomized, placebo-controlled, 
2-period cross-over study of CK-2127107 of older healthy adults with limited mobility. Subjects are randomized (1:1) to placebo or [ADDRESS_438818] of CK -2127107 in tablet form on skeletal muscle fatigue 
assessed as change from baseline versus 14 days of treatment in sum of peak torque during isokinetic knee extensions. 
CY 5021 ([STUDY_ID_REMOVED]) is a Phase 2, double-blind, randomized, placebo- controlled, multiple -
dose study of CK-2127107 in suspension form in two ascending dose cohorts of patient s with 
spi[INVESTIGATOR_352480] 12 and older. The primary objective i s to determine the potential 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  16   PD effects of CK -2127107 API [INVESTIGATOR_352481]. 
3318- CL-3002 ([STUDY_ID_REMOVED]) is a Phase 2, randomized, double blind placebo-controlled, two 
period crossover study in patients with chronic obstructive pulmonary di sease . The dose of 
CK-[ADDRESS_438819] of CK -2127107 in tablet form on physical function in subjects with chronic 
obstructive pulmonary disease. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438820]  of CK -2127107 versus placebo on 
respi[INVESTIGATOR_352482] . 
2.1.1. Primary Efficacy Endpoint 
The primary efficacy endpoint is the change from baseline to Visit Week 12 in the percent 
predicted slow vital capacity (SVC) . 
2.2. Secondary Objectives 
The secondary objectives of this study are:  
• To assess the effect  of CK-2127107 versus placebo on measures of skeletal muscle 
function 
• To assess the effect of CK-2127107 versus placebo on global function 
• To evaluate the safety and tolerability of CK -2127107 administered orally to patients 
with ALS  
• To evaluate the exposure of CK -2127107 and its metabolites, when administered orally 
in tablet form to patients with ALS  in the fed state  
2.2.1. Secondary Endpoints  
• Slope from baseline to Visit Week  12 in the mega -score of muscle strength measured 
by [CONTACT_352516] (HHD) and handgrip dynamometry  
• Change from baseline to Visit Week 12 in the A LS Functional Rating Scale – Revised 
(ALSFRS -R) 
• The incidence and severity of treatment -emergent adverse events (TEAEs)  
• Plasma concentrations of CK -2127107 at  the sampled time points during the study 
2.3. Exploratory Objectives 
The explorator y objectives of thi s study are:  
• To assess the effect  of CK-2127107 versus placebo on respi[INVESTIGATOR_352483] -
assessments made  at home  by [CONTACT_352517]  
• To assess the effect of CK -2127107 versus placebo on disease progression through 
measurement of speech production characteristics over time 
• To assess the effect of CK -2127107 versus placebo on disease progression through 
measurement of handwriting abilities over time  
• To assess the change from baseline to Visit Week 12 in quality of life (as measured by 
[CONTACT_352518] [ ALSAQ -5]) and muscle strength in 
patients on CK-2127107 compared to placebo 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  18   • To assess the change in the slope of decline of measures of function in patients on 
CK-2127107 compared to placebo 
2.3.1. Exploratory Endpoints  
Endpoints assessed as a change from baseline include:  
• Change from baseline to Visit Week 12 in the percent predicted SVC measured at home  
• Change from baseline to Visit Week 12 in the components of voice analysis  
• Change from baseline to Visit Week 12 in the components of handwriting analysis  
• Percent changes from baseline in the strength of the muscle groups from baseline to Visit Week 12 that contribute to the M ega-score at Visit Week 12   
• Change from baseline to Visit Week 12 in the ALSAQ-5 
Endpoints assessed as a change in slope include :  
• Slope of change from baseline to Visit Week 12 in the percent predicted SVC 
• Slope of change from baseline to Visit Week 12 in the ALSFRS-R 
• Slope of change from baseline to Visit Week 12 in percent predicted SVC measured at home 
• Slope of change from baseline to Visit Week 12 in the components of voice analysis 
• Slope of change from baseline to Visit Week 12 in the components of handwriting analysis  
• Slope of change from baseline to Visit Week 12 in the ALSAQ-5 
2.4. Pharmacokinetic / Pharmacodynamic  Objective 
The PK/PD  objectives of this stud y are to characterize the PK of CK -2127107 following multiple 
doses in the fed state at three dose levels in ALS patients as well as to evaluate possi ble 
relationship s between both dose and exposure of CK -2127107 and its PD  effects following  
multiple oral doses in patients with ALS . 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438821] acebo -controlled, dose ranging study of 
CK-2127107 in patients with ALS . 
Approximately 445 eligible ALS patients  will be randomized (1:1:1:1) to receive the following 
doses of CK -2127107 or placebo:  
• 150 mg CK -2127107 twice a day for a 300 mg total daily dose (TDD) 
• 300 mg CK-2127107 twice a day for a 600 mg TDD 
• 450 mg CK-2127107 twice a day for a 900 mg TDD 
• Placebo twice daily  
Study medication should be taken twice daily , approximately 12 hours (± 2 hours) apart , and 
should be taken within the 2 hour period following a meal. 
An overview of the randomized treatment groups is provided in Table 1: 
Table 1: CY 50 22 Randomized, Double -Blind Treatment Groups  
CK-2127107 Placebo  
300 mg TDD 
1 table t (150 mg) of 
CK-2127107 and 
2 placebo tablets twice 
daily for 12 weeks 600 mg TDD 
2 tablets (150 mg) of 
CK-2127107 and 
1 placebo tablet  twice 
daily for 12 weeks 900 mg TDD  
3 tablets (150 mg) of 
CK-[ADDRESS_438822] completed screening and are considered eligible for the study, they will be randomized as described above and stratified by [CONTACT_352519]/non-use and edaravone use/non-use. 
There will be a total of seven  study vi sits for each patient : 
• Screening  
• First Dosing Day (Day 1)  
• Week 2 
• Week 4 
• Week 8 
• Week 12 
• Follow- Up Visit ([ADDRESS_438823] dose of study drug) 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  20   Figure  1: Patient Visit Diagram 
 
PD measures, v ital signs, electrocardiograms ( ECGs ), and c linical laboratory evaluations will be 
performed at Screening and at specified times during the stu dy. Patients will be evaluated at each 
study visit for signs and symptoms of intolerance to study drug. 
3.2. Study Rationale  
CK-[ADDRESS_438824] 
exposure- response analys es. A drug with a similar mechanism of action, tirasemtiv , is currently 
being investigated  in a Phase 3 study in ALS (CY 4031, VITALITY-ALS) and in an open label 
extension study to CY 4031 (CY 4033, VIGOR- ALS) . In a Phase 2 b study (CY 4026, 
BENEFIT -ALS), patients on tirasemtiv  had a reduction in the rate of decline in SVC  compared 
to placebo . 
3.3. Dose  Rationale  
CK-2127107 will be administered as 150 mg tablets , at doses of 300 mg /day,  600 mg/day, or 
900 mg/day  TDD in the fed state  as described above in Table 1. Based on initial population PK 
modeling of the Phase 1 study data, these three doses yield predicted  mean  Cmax values (%CV) 
ranging from approximately  1789 (44.1) to 5543 (35.9) ng/mL  assuming exposures in ALS 
patients are similar to healthy  volunteers. The doses selected in the current study should produce 
plasma concentrations that span the PD  range observed in the healthy volunteer population in 
Study CY 5013.   

CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438825] force increases at 10 Hz . 
Figure  2: CY 5013: Increases in Force during Nerve Stimulation in Healthy Volunteers  
 
Based on prior clinical experience, the doses selected for this study are expected to be well  
tolerated and potentially pharmacodynamically active. The information obtained in this study will guide the selection of doses for a potential Phase 3 clinical stud y of CK-2127107 in patients  
with ALS . 

CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438826] 445 patients 
with ALS who fulfill the eligibility criteria . 
4.1. Inclusion Criteria 
Patients  who meet all the following criteria may be included in the study:  
1. Able to comprehend and willing to sign an Informed Consent Form (ICF) 
2. Males or females  between the ages o f 18 and 80 years of age , inclusive 
3. Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-
supported probable, probable, or definite criteria for a diagnosis of ALS according to the 
World Federation of Neurology El Escorial criteria  published in 2000 ( Brooks, Miller et 
al. 2000) ≤ 24 months prior to screening 
4. Upright S VC ≥ 60% of predicted for age, height and sex at screening  
5. Able to swallow tablets  
6. A caregiver (if one is needed)  
7. Able to perform reproducible pulmonary function tests 
8. Pre-study clinical laboratory findings within the normal range or, if outside the normal 
range, deemed not clinically significant by [CONTACT_737] 
9. Male patients , who have not had a vasectomy and a confirmed zero sperm count, must 
agree after receiving the first dose of study drug  until [ADDRESS_438827] dose to  do 
either of the following : 
• use a condom during sexual intercourse with female partners who are of reproductive 
potential AND to have female partners use an additional effective means of 
contraception (e.g., diaphragm plus spermicide, or oral contraceptives) 
OR  
• abstain from sexua l intercourse  
10. Female patients must be post-menopausal (≥ 1 year) OR sterilized, OR if of childbearing 
potential (i.e., females who have had their first period unless they are anatomically and physiologically incapable to become pregnant) , must: 
• not be breastfeeding , 
• have a negative pregnancy test,  
• have no intention of becoming pregnant during the course of the study, AND  do 
either of the following:  
− use contraceptive drugs or devices as detailed in item number [ADDRESS_438828] dose of study drug AND require male partners to use 
a condom during sexual intercourse 
OR 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  23   − abstain from heterosexual intercourse from Screening until [ADDRESS_438829] 30 days prior to screening 
and not planning to start edaravone during the course of the study. Two cycles of dosing 
are defined as having completed Cycle 1 infusion, which is 14 consecutive days of intravenous ( IV) edaravone followed by 14 days off edaravone, and Cycle 2, which is 10 
out of 14 days of IV edaravone. 
4.2. Exclusion Criteria  
Any of the following will exclude potential patient s from the study: 
1. At the time of screening, a ny use of non- invasive ventilation , e.g. continuous positive 
airway pressure, noninvasive bi-level positive airway pressure or noninvasive volume ventilation , for any portion of the day, or mechanical ventilation via tracheostomy, or on 
any form of oxygen supplementation 
2. Neurological impairmen t due to a condition other than ALS  
3. Presence at screening of any medically significant cardiac, pulmonary, gastrointestinal, 
musculoskeletal, or psychiatric illness that might interfere with the patient’s ability to 
comply with study procedures or that might confound the interpretation of clinical safety or efficacy data, including, but not limited to : 
a. A pulse <40 or >100 bpm; mean systolic blood pressure >180 mm Hg; mean diastolic 
blood pressure >100 mm Hg (based on measurements taken after rest for 3 minutes)  
that persist on [ADDRESS_438830] 2 minutes apart.  
b. Clinically significant ECG abnormalities that require medical attention (i.e., persistent atrioventricular conduction block >first degree, or acute myocardial ischemic changes)  
c. [LOCATION_001] H eart Association  Class II or greater congestive heart failure  
d. Chronic obstructive pulmonary disease or asthma requiring daily use of 
bronchodilator medications 
e. Gastrointestinal disorder that is likely to  impair absorption of study drug from the 
gastrointestinal tract  
f. ALT or aspartate aminotransferase (AST) greater than or equal to 3- times  the upper 
limit of normal (ULN) or has total bilirubin  (TBL)  greater than  or equal to  2-times the 
ULN at screening . These assessments may be repeated  at the Investigator’s discretion 
(within the screening window). 
g. Poorly controlled or brittle diabetes mellitus  
h. Amputation of a limb  
i. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient’s ability to understand and/or comply w ith study procedures and provide informed 
consent 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  24   j. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of 
the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last five years  
k. Any other condition, impairment or social circumstance that, in the opi[INVESTIGATOR_689], would render the patient not suitable to participate in the study 
l. Patient judged to be actively suicidal or a suicide risk by [CONTACT_737]  
m. Patien t has estimated glomerular filtration rate (eGFR) less than 40 mL/min/1.73 m
2 
calculated by [CONTACT_352520][INVESTIGATOR_10444] ( CKD- EPI) 
cystatin equation  based on a cystatin C measurement at baseline  
4. Has taken any investigational study drug within [ADDRESS_438831] 2 years  
10. Use of  a strong cytochrome P450 ( CYP ) 3A4 inhibitor within [ADDRESS_438832] dose of study drug 
11. Use of a medication that is an OCT1/OCT2 substrate within 7 days (see Appendix B )  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  25   5. STUDY P ROCEDURES  
5.1. Screening  
A signed ICF will be obtained from each patient  prior to performin g any study- specific 
procedures. A copy of the ICF will be retained in the study file and a copy will be provided to 
the patient . 
The following screening procedures will be performed for all potential patient s at a visit 
conducted within 14 days of study entry: 
1. Demographic data  
2. Medical history , including review of concomitant medications, tobacco and alcohol usage 
3. Review of inclu sion/exclusion criteria  
4. Height, body weight, and calculation of body mass index (BMI) 
5. Routine physical examination  
6. Neurological  examination  
7. 12-lead ECG  
8. Vital signs, including temperature, heart rate, blood pressure , and respi[INVESTIGATOR_352484] 3 minutes  
9. Clinical laboratory evaluations, including complete blood count (CBC) and white blood 
cells ( WBC ) with differential, serum chemistries, cystatin C , urinalysis (UA) , and thyroid 
stimulating hormone (TSH)  
10. Pregnancy test for all females of childbearing potential  
11. SVC  
12. Muscle strength measurements  
13. ALSFRS -R 
14. Voice recording  
15. Fine motor measurement  of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
16. Ashworth score 
17. ALSAQ -[ADDRESS_438833] Screen  (BDI -Fast Screen ) 
Once a patient is confirmed eligible to participate and before the first dose on Day 1, patients 
will be randomized to receive either CK-[ADDRESS_438834] Dosing Day (Day 1) 
Prior to study drug dosing on Da y 1, the following procedures will be performed: 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438835] 3 minutes  
2. Weight  and calcu lation of BMI 
3. Clinical laboratory evaluations, including CBC and WBC with differential, serum 
chemistries, cystatin C  and UA 
4. PK blood sample 
5. SVC  
6. Muscle strength measurements  
7. ALSFRS -R 
8. Voice recording  
9. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
10. Ashworth score 
11. Falls a ssessment  
12. ALSAQ -[ADDRESS_438836] Health Economic Outcomes Measures  
14. AE/SAE evaluation and concomitant medication assessment (since last visit)  
15. BDI-Fast Screen  
Patients will receive their first dose of study drug ( CK-2127107 or placebo) within [ADDRESS_438837] dose of study drug is given: 
16. PK blood sample at [ADDRESS_438838]-dose 
Training will also be provided to the patient for the measurements patients will perform at home.  
•  For patients who have access to a mobile device, the app lication  will be downloaded 
to the device and instructions provided as detailed in the study manual on recording voice. 
• All patients will be trained in performing SVC  using a portable spi[INVESTIGATOR_14007] (if the 
device is suitable  for us e in that region) as detailed in the study manual.  
Home voice recordings and SVC testing will be performed by [CONTACT_352521] 1. 
Patients will be given an adequate supply of study drug (CK-2127107 or placebo) to t ake twice 
daily for [ADDRESS_438839] the date and time of 
twice daily study drug administration.  
5.3. Week 2 Visit  
Prior to study drug dosing at  the Week 2 Visit, the followin g procedures will be performed: 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438840] 3 minutes  
2. Weight  and calcu lation of BMI  
3. PK blood sample  
4. Clinical laboratory evaluations, including CBC and WBC with differential, se rum 
chemistries, cystatin C  and UA 
5. SVC  
6. Muscle strength measurements  
7. ALSFRS -R 
8. Voice recording  
9. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
10. Ashworth score 
11. Falls assessment  
12. ALSAQ -[ADDRESS_438841] Health Economic Outcomes Measures  
14. AE/SAE evaluation and concomitant medication assessment (since last visit)  
15. BDI-Fast Screen  
Patients will receive their dose of study drug (CK -2127107 or placebo) within 2 hours of eating a 
meal . Patients should be reminded to bring their unused study drug with them to the clinic and 
that they will be taking their dose of study drug while at the clinic . The following assessment 
will be performed after the dose of study drug is given: 
16. PK blood sample at [ADDRESS_438842] already been  given their  supply of study drug ( CK-2127107 or placebo) to 
take twice daily at home until their next clinic visit at Week 4. A dosing diary will be provided 
for patients to record the date and time of twice daily study drug administration.  
5.4. Week 4 Visit  
Prior to study drug dosing at  the Week 4 Visit, the following procedures will be performed:  
1. 12-lead ECG  
2. Vital signs, includin g heart rate, blood pressure, and respi[INVESTIGATOR_352485] 3 minutes  
3. Weight  and calcu lation of BMI  
4. PK blood sample 
5. Clinical laboratory evaluations , including CBC and WBC with differential, serum 
chemistries, cystatin C  and UA 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  28   6. SVC  
7. Muscle strength measurements  
8. ALSFRS -R 
9. Voice recording  
10. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
11. Ashworth score 
12. Falls assessment  
13. ALSAQ -[ADDRESS_438843] Health Economic Outcomes Measures  
15. AE/SAE evaluation and concomitant medication assessment (since last visit)  
16. BDI-Fast Screen  
Patients will receive their dose of study drug (CK -2127107 or placebo) within 2 hours of eating a 
meal . 
Patients will be given an adequate supply of study drug ( CK-2127107 or placebo) to take twice 
daily for [ADDRESS_438844] the date and time of twice daily study drug administration.  
5.5. Week 8 Visit  
Prior to study drug dosing at  the Week 8 Visit, the following procedures will be performed: 
1. Vital signs, including heart rate, blood pressure , and respi[INVESTIGATOR_352486] 3 minutes  
2. Weight  and calcu lation of BMI  
3. PK blood sample 
4. SVC  
5. Muscle strength measurements  
6. ALSFRS -R 
7. Voice recording  
8. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
9. Ashworth score 
10. Falls assessment  
11. ALSAQ -[ADDRESS_438845] Health Economic Outcomes Measures  
13. AE/SAE evaluation and concomitant medication assessment (since last visit)  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438846] Screen  
Patients will receive their dose of study drug (CK -2127107 or placebo) within 2 hours of eating a 
meal . 
Patients will be given an adequate supply of study drug ( CK-2127107 or placebo) to take twice 
daily for [ADDRESS_438847] dose of study drug at the Week 12 Visit, the following procedures will be 
performed:  
1. Vital signs, including heart rate, blood pressure, and respi[INVESTIGATOR_352485] 3 minutes  
2. Weight  and calcu lation of BMI  
3. PK blood sample 
4. Clinical laboratory evaluations, including CBC and WBC with differential, ser um 
chemistries, cystatin C  and UA 
5. SVC  
6. Muscle strength measurements  
7. ALSFRS -R 
8. Voice recording  
9. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
10. Ashworth score 
11. Falls assessment  
12. ALSAQ -[ADDRESS_438848] Health Economic Outcomes Measures 
14. AE/SAE evaluation and concomitant medication assessment (since last visit)  
15. BDI-Fast Screen  
Patients will receive their dose of study drug (CK -2127107 or placebo) within [ADDRESS_438849] dose of study drug is given:  
16. PK blood sample at [ADDRESS_438850]-dose  
5.7. Follow -Up Visit  
The following procedures will be performed at a Follow- Up Visit 4 weeks  after each patien t’s 
final dose of study drug: 
1. 12-lead ECG  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438851] for all females of childbearing potential 
8. SVC  
9. Muscle strength measurements  
10. ALSFRS -R 
11. Voice recording  
12. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
13. Ashworth score 
14. Falls assessment  
15. ALSAQ -[ADDRESS_438852] Health Economic Outcomes Measures  
17. AE/SAE evaluation and concomitant medication assessment (since last visit)  
18. BDI-Fast Screen  
5.8. Early Termination Visit  
If a patient decides to terminate early from the study , they should be seen in the clinic as soon as 
possible following discontinuation of study drug. The following procedures will be performed: 
1. 12-lead ECG  
2. Vital signs including heart rate, blood pressure , and respi[INVESTIGATOR_352487] 3 minutes  
3. Weight  
4. Abbreviated physical examination  
5. Neurological examination  
6. Clinical laboratory evaluations, including CBC and WBC with differential, serum 
chemistries , cystatin C  and UA 
7. SVC  
8. Muscle strength measurements  
9. ALSFRS -R 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  31   10. Voice recording  
11. Fine motor measurement of handwriting and tracing of forms via an app (if the device is 
suitable  for use in that region) 
12. Ashworth score 
13. Falls assessment  
14. ALSAQ -[ADDRESS_438853] Health Economic Outcomes Measures  
16. AE/SAE evaluation and concomitant medication assessment (since last visit)  
17. BDI-Fast Screen  
If a patient decides to terminate early from the study but does not wish to return to the clinic for 
an Early Termination Visit, they should be contact[CONTACT_352522]: 
1. ALSFRS -R 
2. ALSAQ -[ADDRESS_438854] Health Economic Outcomes Measures  
4. Falls Assessment  
5. AE/SAE evaluation and concomitant medication assessment (since last visit)  
5.9. Visit Windows  
To aid in scheduling patient visits, the following study visit windows are considered acceptable 
(Table 2). If a patient visit must be scheduled outside the visit window, the Medical Monitor 
should be contact[INVESTIGATOR_530]. 
Table 2: Visit Windows  
Visit  Visit Window  
Screening  Up to 14 days prior to Day 1 v isit (as per protocol)  
Day [ADDRESS_438855] day of randomized, double -blind dosing  
Week 2 (Day 15)  ± 2 days  
Week 4 (Day 29)  ± 2 days  
Week 8 (Day 57)  ± 4 days 
Week 12 (Day 85)  ± [ADDRESS_438856] dose of study drug ± 4 days 
5.10. Diet Control  
All doses of study drug should be taken within 2 hours following a meal . 
Subjects will abstain from consuming grapefruit  and Seville oranges along with foods or 
beverages containing them from Day 1 through the Follow- Up visit. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  32   5.11. Concomitant Medications  
All prescription drugs, over-the-counter medications, nutraceuticals  and herbal remedies taken 
by [CONTACT_352523]- Up visit should be entered into the 
electronic case report form (eCRF) . Medications that strongly inhibit the activity of CYP3A4 
should be avoided from 7 days before the start of dosing (Day 1) through the last day of dosing 
(End of Week 8). Medications that strongly induce the activity of CYP3A4 should be avoided 
from 14 days before the start of dosing (Day 1) through the last day of dosing (Week 12 ). Please 
refer to Appendix B   for strong inhibitors and inducers of CYP3A4. M edications that are 
OCT1/OCT2 substrates should be avoided from [ADDRESS_438857] the potential to inhibit OCT1 and OCT2-
mediated transport. Please refer to Appendix B   for O CT1/OCT2 substrates that should be 
avoided or used with caution. 
5.12. Pharmacokinetic Sampling  
Blood samples for analysis of CK -2127107, its  metabolite s, and riluzole will be collected from 
patients at the nominal time points listed in  Table 3. 
Table 3: Pharmacokinetic (PK) Samples  
Day Sample Time Points  
Day 1  Pre-dose and 1 (±15 min) hour post -dose  
Week 2 Pre-dose and 1 (±15 min) hour post -dose 
Week  4 Pre-dose 
Week 8 Pre-dose 
Week  12 Pre-dose and 1 (±15 min) hour post -dose 
If an indwelling catheter is u sed, saline flushes will be used. In some cases, sites may be unable 
to obtain the 6 hour timepoint at Week 2 or Week 12 for logistical reasons; these cases should be 
discussed with the medical monitor preferably ahead of time.  
After completion of bioanalysis , remaining plasma samples will b e retained consistent with the 
Sponsor’s standard operating procedures. These samples will not be used for pharmacogenomic 
testing . 
5.13. Clinical Safety Assessments  
5.13.1. Clinical Laboratory Evaluations 
Clinical laboratory evaluations will be collected at Screening , Day 1, Week 2  visit, Week 4 visit, 
Week 12 visit, and  at the Follow-U p Visit as described in Appendix D . 
5.13.2. 12-Lead Electrocardiograms  
A 12 -lead ECG , including ECG parameters of RR, PR, QRS, QT and QTc intervals as well as 
significant findings will be obtained at Screening , Week 4 visit, and  at the Follow-U p Visit. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  33   When 12- lead ECGs are scheduled at the same time as blood draws, the order of evaluation will 
be ECG, vital sign s, and then blood draw. 
5.13.3. Vital Signs  
Heart rate, blood pressure , and respi[INVESTIGATOR_697] (measured after the patient  has been res ting and 
seated for at leas t 3 minutes ), will be obtained at every visit. T emperature will also be obtained at 
the Screening visit.  Height is obtained only at the screening visit. Weight will be obtained at each 
visit; and BMI will be calculated at screening and subsequent visits . 
When vital signs are scheduled at the same time as blood draws, the order of evaluation will be 
ECG, vital sign s, and then blood draw. 
5.13.4. AE Assessments  
Patients will be asked how they are feeling from the first administration of study drug through 
the Follow- Up visit (see Section  7.2). Patient s will also be encouraged to voluntarily report any 
AEs they experience during the study. 
5.13.5. Physical Examinations 
A routine physica l examination will be performed  at Screening , and an abbreviated physical 
examination (consisting of an examination of general appearance, skin, lungs, cardiovascular and abdomen) will be performed at the Follow-U p Visit. 
5.13.6. Neurological Examinations 
A neurological examination will be administered at Screening and at the Follow- Up Visit as 
described in the Study Manual. 
5.13.7. Beck Depression Inventory -Fast Screen  (BDI -Fast Screen)  
The BDI -Fast Screen  will be assessed at all study visits as described in the Study Manual.  
5.13.8. Falls Assessment  
Falls assessment will be performed at each study visit except Screening as described in the Study 
Manual.  
5.13.9. Ashworth Scale  
The Ashworth scale to assess spasticity will be performed at each study visit. Further description 
of the Ashworth Scale can be found in the Study Manual. 
5.14. Clinical and Pharmacodynamic Outcome Measures  
5.14.1. Pulmonary Function  Assessment  
The pulmonary function assessment in this study will be SVC . Pulmonary function assessment 
will be performed at  each study visit as described in the Study Manual. Patients will also perform 
home SVC assessments weekly through the course of the study following Day 1 (if the device is 
suitable  for use in that region) as described in the Study Manual.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438858] access to mobile 
devices weekly at home as described in the Study Manual. 
5.14.5. Fine M otor A ssessment s (Handwriting and F igure T racing ) 
The handwriting and figure tracing assessments will be done a t each study visit ( if the device is 
suitable  for use in that region) as described in the Study Manual.  
5.14.6. ALSAQ -5 
The ALSAQ -5 will be performed at each study visit as described in the Study Manual . 
5.14.7. Health Economic Outcomes Measures  
During the course of the study, if the patient is prescribed and agrees to receive any of the 
following, it will be recorded including the date prescribed : 
• Non-invasive ventilation  
• Gastrostomy tube 
• Manual wheelchair  
• Power wheelchair  
• Augmentative and alternative communication  
5.15. Removal of Patient s from Study Participation  
Patient s will be informed that they are free to discontinue study drug or withdraw from the study 
at any time and for any reason. The Investigator may discontinue study drug or withdraw a 
patient  from the study if, in the Investigator's opi[INVESTIGATOR_1649], it is not in the best interest of the patient  to 
continue the study. Patients may discontinue study drug or withdraw from the study due to the 
following: 
a. A change in compliance with inclusion/exclusion cri teria that is clinically relevant 
and/or affects patient  safety , and/ or study assessments/objectives, etc.  
b. Occurrence of intolerable AEs 
c. Changes in vital signs, ECGs , or clinical laboratory results that, in the opi[INVESTIGATOR_684], pose a significant health risk  
d. Intake of non- permitted concomitant medication that might affect patient  safety or 
study assessments/objectives, etc.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  35   e. eGFR calculated using the CKD- EPI [INVESTIGATOR_352488]  (Inker, Schmid et al. 2012) 
shows a >25% decline compared to baseline (defined as Day 1 or Screening if Day 1 
value is not available)  as long as the decline is not related to dehydration or a 
superimposed reversible process such as infection or nausea. 
f. Changes in liver function tests (LFTs)  as outlined in Appendix C    
g. Receiving any form of stem cell therapy for ALS either as part of a clinical trial or outside of a clinical trial  
h. Having a diaphragmatic pacing system implanted either as part of a clinical trial or outside of a clini cal trial  
i. Initiating edaravone after screening.  
j. Initiating riluzole after screening.  
k. Initiating  gene therapy for ALS either as part of a clinical trial or outside of a clinical 
trial after screening . 
Patients should be strongly encouraged to perform the early termination visit as soon as possible 
following last dose of study drug taken, and the F ollow -Up Visit should be performed [ADDRESS_438859] dose taken of study medication . In addition, they should be encouraged to return for all 
remaining study visits and assessments  (with the exception of 12- lead ECG, clinical laboratory 
and PK sampling) for the duration of the study following study drug discontinuation. These 
remaining study visits should be performed according to the original study visit windows. 
Patients who decide to start or stop edaravone or riluzole  after screening and before 
randomization, will no longer be eligible to be randomized and should not be followed 
subsequently. If a patient decides to start edaravone or ri luzole after randomization, they will be 
terminated from taking study medication once that is known by [CONTACT_779]. They should return to 
the clinic for their early drug termination visit as soon as possible  following last dose of study 
drug taken  and return [ADDRESS_438860] the 
inform ation if the patient is willing (see Section  5.8).  
Notification of discontinuation will immediately be made to the Sponsor’s Medical Monitor. In case of withdrawal  of study participation, efforts will be made to perform Early Termination 
(Section  5.8) and Follow-Up visit assessments ( Section  5.7). The date the patient  is withdrawn 
from the study and the reason for discontinuation will be recorded on the patient ’s eCRF. All 
patient s who prematurely discontinue from the study for AEs will be followed for up to [ADDRESS_438861] stabilized. 
The primary reason for a patient  prematurely withdrawing from the study should be selected 
from the following categories and documented in the source documents: 
a. Patient  Death  
b. Adverse Event:  One or more clini cal or laboratory events which, in the medical 
judgment of the Investigator, are grounds for discontinuation even if the event does 
not appear to be related to study medication. The patient  may withdraw because of an 
AE even if the Investigator does not feel that the event is grounds for discontinuation. 
c. Protocol Violation:  The patient ’s findings or conduct failed to meet the protocol 
entry criteria or failed to adhere to the protocol requirements 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  36   d. Patient  Withdrawal of Consent :  Patient  desires to withdraw from further participation 
in the study and reason for doing so. 
e. Administrative/Other:  Any cause of premature termination from the study other than 
the above, such as illness of investigator, loss of study drug, or termination of study by [CONTACT_1034]. 
5.16. Assessment of Safety  
An independent Data Monitoring Committee (DMC) will periodically assess patient safety in an 
unblinded manner during the course of the study. No unblinded data will be accessible to site 
staff, the Sponsor, study monitors, and personnel of the electronic data capture vendors before 
the database is locked . The specific activities and responsibilities of the DMC are defined in the 
DMC Charter for CY 5022. 
Dosing of an individual will be stopped and not resumed if treatment- related AEs, chan ges in 
vital signs, ECGs, or clinical laboratory results are observed and these changes pose a significant 
health risk, in the opi[INVESTIGATOR_352489]. A blood 
sample for PK analysis should be collected at the time  of the event or as close as possible to the 
time of the event . 
In the event of a confirmed, marked hepatic abnormality as defined in Appendix C   (Liver Safety 
Monitoring and Assessment), it is the Investigator’s responsibility to ensure contact [CONTACT_352524] (i.e., within [ADDRESS_438862] possible time point). Patient s with AEs of hepatic origin accompanied by L FT abnormalities should be carefully 
monitored. 
5.17. Study Drug Interruption  
Patients who do not take the total assigned daily dose of study drug due to conditions of hospi[INVESTIGATOR_352490]. The Medical Monitor should be contact[CONTACT_5365] a patient who has discontinued treatment for more than one 
week (prolonged study drug interruption). 
If study drug interruption for more than one week has occurred, the Investigator should evaluate 
the patient in  clinic to ensure that it is safe for the patient to resume study drug dosing and 
consult with the Medical Monitor for the appropriate course of action. 
5.18. Study D iscontinuation  
The study may be discontinued by [CONTACT_352525]: 
• Excessive rates of AEs  
• Medical or ethical reasons affecting the continued performance of the study  
• Difficulties  in the recruitment of patient s 
• A decision to cease or delay further development of the drug 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438863]  
This is  a double-blind, placebo-controlled study. As such, the site pharmacy staff, the 
Investigator, the patient, remaining study site clinical staff , and the Sponsor will be blinded to 
treatment assignment . 
CK-2127107 study drug  is supplied as immediate release, white to off -white, modified capsule-
shaped tablets at a dose strength of 150 mg of CK-2127107 per tablet, which are to be stored 
under secure conditions at ≤25°C (77°F) with excursions allowed up to 30°C (86°F).  
Matching placebo tablets  will be supplied and should also be stored at controlled room 
temperature under secure conditions. 
Active CK -2127107 tablets contain 150 mg of CK-2127107 plus excipi[INVESTIGATOR_840]. Placebo tablets 
contain excipi[INVESTIGATOR_190852]. 
Table 4: Study Drug  
Study Drug  CK-2127107  Placebo for CK -2127107  
Form  Tablet  Tablet  
Supplier  Cytokinetics, Inc.  Cytokinetics, Inc.  
Manufacturer  Patheon, Inc.  Patheon, Inc.  
CK-2127107 and matching placebo tablets will be supplied to the clinical site in blister strips 
inside labeled wallets. Patients will receive one or more wallets of study drug, CK -2127107 or 
matching placebo at the appropriate visit. Each wallet is sufficient for on e week of dosing, plus 
overage. Double- blind wallets will be labeled with a unique random kit number. 
The study research coordinator or designated site staff will be responsible for patient 
randomizations, using an interactive web response system ( IWRS ). 
6.2. Dose Administration  (CK-2127107 or Placebo)   
This study drug will be administered orally as tablets to patients with ALS . Doses ( CK-2127107 
or placebo) for each of the treatment groups will be dispensed in accordance with the study randomization prior to the patient’s first dose. 
6.3. Dosing Diary  
A dosing diary  will be maintained by [CONTACT_352526] . The dosing diary should be returned at each clinic visit. 
6.4. Randomization  Schedule and Removal of Blind   
An IWRS will provide patient randomization assignments for this study . The site pharmacist or 
other qualified person responsible for randomizing patients will receive the appropriate kit 
numbers through the IWRS and provide it to the site staff who will be distributing study drug to the patient . RANDOMIZATION INFORMATION MAY BE MADE AVAILABLE TO THE 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  38   INVESTIGATOR ONLY IN THE EVENT OF A MEDICAL EMERGENCY OR AN AE THAT 
NECESSITATES IDENTIFICATION OF THE STUDY DRUG ( CK-2127107 or placebo) FOR 
THE WELFARE OF TH AT PATIENT . Except in a medical emergency, the Investigator (or 
designee) and study site clinical staff will remain blinded during the conduct of the study and until such time that all discrepancies in the clinical database are resolved (i.e., at the time of the 
database lock) . The date/initials and reason for study blind removal by [CONTACT_11219]/or 
clinical staff will be documented . The Investigator will contact [CONTACT_352527] . 
6.5. Study Drug Accountability and Disposal   
The site pharmacist or other qualified person responsible for managing study drug supplies will maintain an accurate record of the receipt of the investigational study drug as shipped by [CONTACT_1034] (or designee), including the kit number and date received. One copy of this receipt will 
be returned to the Sponsor when the contents of the investigational study drug shipment have been verified . An accurate drug disposition record will be kept, specifyi ng the study drug 
provided to each patient  and the dates of dose administration. This drug accountability record 
will be available for inspection at any time . At the completion of the study, the original drug 
accountability record will be available for review by [CONTACT_117605]. 
The patient should be instructed to return all unused study drug to the designated clinical site 
staff at each study visit. Study drug accountability is to be conducted by [CONTACT_352528]. The dosing diaries should also be referenced when completing drug accountability. 
All unused drug supplies will be returned to the Sponsor (or designee) or disposed of by [CONTACT_352529] , per the Sponsor’s (or designee’s) instructions at the end of the study. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  39   7. ADVERSE  EVENTS  
7.1. Definition s 
7.1.1. Adverse Event  
As defined by [CONTACT_5787] (ICH), an AE is any untoward 
medical occurrence in a patient or clinical investigation subject administered an inves tigational 
product, and which does not necessarily have to have a causal relationship with the 
investigational product. An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exace rbated) temporally 
associated with the use of the investigational product. 
Examples of an AE:  
• Conditions newly detected or diagnosed after the administration of the investigational 
product, including conditions that may have been present but undetected prior to the 
start of the study  
• Conditions known to have been present prior to the start of the study that increase in severity or frequency after the administration of the investigational product 
• Signs, symptoms, or the clinical sequelae of a suspected drug interaction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose (overdose per se should not be reported as an AE term ) 
• Abnormal laboratory findings (e.g., clinical chemistry, hematology) or other 
abnormal assessments (e.g., ECGs, vital signs, etc.) that are considered  by [CONTACT_51875] a clinically significant change after the first dose of the investigational 
product. The Investigator will exercise his/her medical and scientific judgment in deciding whether an abnormal laboratory finding  or other abnormal assessment is a 
clinically significant change after the first dose of the investigational product. 
Issues Not Considered AEs: 
• Medical or surgical procedures (e.g., appendectomy). The AE is the condition that 
leads to the procedure (e.g., appendicitis) if it qualifies according to the definition 
above. 
• Hospi[INVESTIGATOR_352491]. Examples 
include: 
− hospi[INVESTIGATOR_352492] a caregiver outside of 
the hospi[INVESTIGATOR_352493] , OR  
− hospi[INVESTIGATOR_352494] 
• Fluctuations of pre-existing disease(s) or condition(s) present or detected at the start 
of the study that do not represent a clinically significant change after the first dose of 
the investigational product. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  40   • Abnormal laboratory or test findings that are not assessed by [CONTACT_5256] a 
clinically significant change after the first dose of the investigational product. 
7.1.2. Seriou s Adverse Event  
A serious adverse event (SAE) is any AE that:  
a. Results in death  
NOTE: Death is selected as a seriousness  criterion ONLY  when the event is the cause 
of death. Death is an outcome and the event which led to the death should be the 
reported event term . 
b. Is life -threatening  
NOTE: The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the patient was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe, prolonged, 
or untreated. 
c. Requires hospi[INVESTIGATOR_12331]: Hospi[INVESTIGATOR_352495]-patient for any length of time. Emergency r oom treatment does not qualify for 
this category, but may be appropriately included in category f (see below). If a 
complication prolongs the hospi[INVESTIGATOR_352496], the complication will be considered an additional SAE. When in doubt as to 
whether ‘hospi[INVESTIGATOR_059]’ occurred, consult the Medical Monitor. 
Hospi[INVESTIGATOR_352497]. It will be considered an 
outcome of an AE. For example, hospi[INVESTIGATOR_352498] a pre-
existing condition that did not worsen after the first dose of the investigational 
product will not be considered an AE. 
d. Results in disability/incapacity  
NOTE: The term disability means a substantial or permanent disruption of a person’s 
ability to conduct normal life functions. This definition is not intended to include 
experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g. 
sprained ankle) that may temporarily interfere with or prevent everyday life functions 
but do not constitute a substantial or permanent disruption. 
e. Is a congenital anomaly/birth defect  
f. Is an important medical event 
NOTE: Medical and scientific judgment should be exercised in deciding if an event 
should be report ed as serious. Important medical events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_352499]. Examples of such events are 
intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  41   of drug dependency or drug abuse. If in doubt as to whether or not an event qualifies 
as an “important medical event”, consult the Sponsor’s Medical Monitor. 
7.2. Collection of  AEs/SAEs  
During each scheduled visit, ask about potential AEs or SAEs  using the following standard 
questions: 
1. Have you had any medical problems since your last visit? 
2. Have you taken any new medications since your last visit? 
7.3. Recording and Reporting of AEs /SAEs  
7.3.1. Recording and Reporting of AEs 
Events occurring between the Scre ening Visit and just prior to the first dose of the 
investigational product on Day 1 should be recorded in the Medical History eCRF unless the event is related to a protocol -mandated procedure. If the event is deemed related to a protocol -
mandated procedur e (e.g., hematoma at the puncture site) and deemed clinically significant by 
[CONTACT_737], the event should be reported as an AE or an SAE (if applicable).  
AEs will be documented from the first administration of the investigational product through the 
Follow- Up Visit . The  Investigator will review all documentation (e.g., hospi[INVESTIGATOR_1088], 
laboratory and diagnostic reports) relevant to the event. A diagnosis will then be determined based on signs, symptoms, and/or other clinical information. The d iagnosis and not the 
individual signs/symptoms should be reported  as the AE  term . 
ALS progression and signs /symptoms  that are expected as part of ALS progression (see 
Section  7.4.3) will not be collected  as AEs unless they meet seriousness criteria and should be 
recorded as SAE s. 
7.3.2. Recording and Reporting of SAEs  
If an AE meets any of the seriousness criteria (see Section  7.1.2
), it must be reported using the 
SAE report form within 24 hours of the site’s knowledge . At a minimum, the following 
information should be included: 
• Patient number 
• Event term, including an onset date and stop date, if applicable, and a brief 
description 
• Seriousness criterion/criteria  
• Causality assessment in relation to the investigational product  
If all information regarding the SAE is not initially available, the site should still report the SAE 
within 24 hours of awareness/discovery. Additional information should be reported when it 
becomes available and no later than 24 hours after receipt of such information. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  42   7.4. Evaluating AEs and SAEs  
7.4.1. Assessment  of Severity  
The Investigator should assess the severity of each AE /SAE . The severity of AEs /SAEs  will be 
assessed by [CONTACT_20526] a Grade of 1, 2, 3, 4 or 5 according to the National Cancer Institute 
Common Terminology Criteria for Adve rse Events (CTCAE ), version 4.0, except for ALT, AST, 
and TBL  levels as described in Appendix C . 
When an AE/SAE  cannot be graded by [CONTACT_3989] , the following severity grade may be used: 
• Grade 1 (Mild): Aware of sign or symptom, but easily tolerated  and intervention is 
not indic ated 
• Grade 2 (Moderate): Discomfort enough to cause interference with usual activity, local or non-invasive intervention is indicated 
• Grade 3 (Severe): Incapacitating with inability to work or do usual activity, not immediately life -threatening; hospi[INVESTIGATOR_352500]  
• Grade 4 (Life- Threatening): Refers  to an event in which the patient  was, in the view 
of the Investigator, at risk of death at the time of the event. (This category is not to be used for an event that hypothetically might have caused death if it were more 
severe.) ; urgent intervention is indicated  
• Grade 5 (Fatal): Death related to AE  
Severity  should not be confused with seriousness. Severity is a category for rating the intensity 
of an event, and an event becomes serious when it meets one of the outcomes described in 
Section  7.1.2 “Serious Adverse Event”. 
7.4.2. Assessment of Causality  
The Investigator will assign causality to each SAE  (related or unrelated) . When assessing 
relationship to study drug, the Investigator will consider the following factors: 
• Temporal association between the administration of the investigational product and 
the event  
• Cessation of the AE following discontinuation of dosing 
• Recurrence of the AE with reintroduction of study drug, if performed 
• Similarity to known class effects  
• Alternative causes, such as:  
− Known effects of concomitant medications  
− Pre-existing risk factors  
− Concurrent illnesses 
The assessment of causality will be based on the information available, and may be changed 
upon receipt of additional information. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  43   7.4.3. Assessment of Expectedness  
ALS  is a progressive and uniformly fatal neurodegenerative disorder associated with relentlessly 
progressive loss of motor function, including appendicular, craniobulbar, and respi[INVESTIGATOR_352501]. The  following events , in addition to death due to ALS 
progression, are anticipated t o occur in the study population as signs/symptoms of ALS 
progression which may or may not lead to hospi[INVESTIGATOR_059].  
Table 5: Med DRA Preferred Terms  
MedDRA Preferred Terma MedDRA Preferred Terma 
Dysarthria  Muscle spasticity  
Dysphagia  Muscle weakness  
Dyspnoea Pneumonia aspi[INVESTIGATOR_352502] /Abnormal loss of weight 
Muscle spasms  
a MedDRA  Version 19.1 
7.5. Follow -Up of AEs  and SAEs  
After the initial recording of an AE /SAE , the Investigator should proactively follow the patient . 
Non-serious AEs that are still ongoing at the end of the study should be reviewed by [CONTACT_149558] f urther follow up is required. The Investigator will document on the 
AE eCRF any/all ongoing non-serious AEs that will not be followed up further after the patient  
exits the study . If in doubt, the Investigator should consult the Medical Monitor. 
All SAEs should be followed until resolution, until the condition stabilizes, or until the patient  is 
lost to follow -up. Once the seriousness criterion no longer appl ies to the SAE  (e.g., patient was 
discharged) , the corresponding AE eCRF page should be updated . All relevant additional 
information collected regarding an SAE, including laboratory test reports, consultation reports from other health care professionals, discharge summaries, or other information should be 
transmitted to Cytokinetics with the follow -up SAE report form  within [ADDRESS_438864] of supplemental 
measurements and/or evaluations to elucidate as fully as possible the nature and/or causality o f 
any AE /SAE . 
If a patient  dies during participation in the study or during the follow-up period, the Investigator 
will provide Cytokinetics  with a copy of any post-mortem findings, including an autopsy report 
if obtainable. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438865]-Study AEs /SAEs  
A post- study AE /SAE  is defined as any event that occurs outside of the AE detection period 
defined in Section  7.3.1. 
Investigators are not obligated to actively solicit AEs from former study participants . However, 
if the Investigator learns of an SAE that he/she considers reasonably related to the investigational 
product at any time after a patient  has been terminated  from the study, the Investigator will 
promptly notify Cytokinetics . 
7.7. Pregnancy  
Pregnancy is not an AE; however, information on pregnant female patients  and partners of male 
patients  will be collected if the pregnancy occurs after the patient  receives the first dose of the 
investigational product until [ADDRESS_438866] dose. The pregnancy information and its 
outcome will be collected using the Pregnancy Report Form. If the pregnancy occurs in a partner 
of a male patient , the partner’s consent will be obtained before collecting information regarding 
the pregnancy and its outcome. 
If the pregnancy test (urine or serum) is positive, the pregnancy should be immediately reported 
to the Investigator and the Sponsor. Any female patient who becomes pregnant during the study 
is not eligible to continue the study and should complete the study procedures as soon as 
possible. 
If a partner of a male patient becomes pregnant during the study , the male patient may opt to 
continue his participation but must use barrier method (condom) to prevent fetal exposure. 
Accidental, therapeutic, or spontaneous abortions and congenital anomalies or birth defects will 
be reported as SAEs.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438867] dose of study medication unless otherwise specified. Missing data will not be imputed 
unless otherwise specified . 
8.1.2. Sample Size and Randomization 
Approximately 445 p atients will be randomized to receive either one of the three CK -2127107 
doses (300 mg /day, 600 mg/day and 900 mg/day TDD) or matching placebo tablets in a ratio of 
1:1:1:1. Randomization will be stratified by [CONTACT_352519]/non-use and edaravone use/non-use. The 
dropout rate at Visit Week 12 is estimated to be 10%, thus approximately [ADDRESS_438868] of CK -2127107 on the 
change from baseline to Week 12 in percent predicted SVC will be analyz ed using a mixed 
model for repeated measures (MMRM) with the contrast ( -5, -1, 3, 3) to reflect the assumed 
relationship for the placebo, 300 mg/day, 600 mg/day and 900 mg/day dose groups . The analysis 
is estimated to provide 90% power to detect 2.75, 5.5 and 5.5 percentage points advantage over 
placebo  for the 300 mg/day, 600 mg/day and 900 mg/day CK -2127107 dose groups, 
respectively,  in change from baseline of percent predicted SVC, at the end of the double-blind 
treatment  (Visit Week 12). This calculatio n is based on a two -sided test with alpha set at 0.[ADDRESS_438869] deviation of 14 percentage points. 
8.2. Analysis Sets 
8.2.1. Full Analysis Set (FAS)  
The FAS will consist of all randomized patients who receive at least one dose or portion of a 
dose of study drug  and who have a baseline and at least one post- baseline efficacy assessment  
during the double- blind treatment.  
8.2.2. Safety Analysis Set (SAS)  
The SAS will consist of all randomized patients  who receive at least one dose or portion of a 
dose of study drug. 
8.2.3. Pharmacokinetics Analysis Set (PK S) 
The PKS  will consist of all randomized patient s who have at least one evaluable plasma 
concentration of CK-2127107, provided they have no major protocol violations that could affect the PK of CK-2127107.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  46   8.3. Endpoint s 
8.3.1. Efficacy Endpoints 
[IP_ADDRESS]. Primary Efficacy Endpoint 
The primary efficacy endpoint is the change from baseline to Visit Week 12 in the percent SVC. 
[IP_ADDRESS]. Secondary Efficacy Endpoints 
• Slope from baseline to Visit Week 12 in the mega -score of muscle strength measured 
by [CONTACT_352530]  
• Change from baseline to Visit Week 12 in the ALSFRS-R 
[IP_ADDRESS]. Exploratory Efficacy Endpoints 
Change from Baseline Endpoints  
• Change from baseline to Visit Week 12 in the percent predicted SVC measured at 
home  
• Change from baseline to Visit Week 12 in the components of voice analysis  
• Change from baseline to Visit Week 12 in the components of handwriting analysis  
• Percent changes from baseline in the strength of the muscle groups from baseline to 
Visit Week 12 that contribute to the M ega-score at Visit Week 12  
• Change from baseline to Visit Week 12 in the ALSAQ-5 
Slope Endpoints:  
• Slope of change from baseline to Visit Week 12 in the percent predicted SVC 
• Slope of change from baseline to Visit Week 12 in the ALSFRS-R 
• Slope of cha nge from baseline to Visit Week 12 in percent predicted SVC measured 
at home  
• Slope of change from baseline to Visit Week 12 in the components of voice analysis  
• Slope of change from baseline to Visit Week 12 in the components of handwriting analysis  
• Slope of change from baseline to Visit Week 12 in the ALSAQ-5 
8.3.2. Safety Endpoints  
The safety endpoints are listed in the following: 
• The incidence and severity of TEAEs  
• Clinically important changes in safety assessment results [including, as appropriate, 
vital signs, clinical laboratory tests, ECGs, Ashworth score, falls assessment, physical 
and neurological examinations, BDI -Fast Screen  and suicidality assessment].  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  47   8.3.3. Pharm acokinetic Measurements  
The plasma concentration s of CK -2127107 and possible metabolites  will be measured at the 
sampled  time points during the study. 
8.4. Statistical Analysis  
8.4.1. Patient Disposition  
The number and percentage of patient s randomized, receiving any study drug, completing the 
study, prematurely discontinuing treatment and prematurely discontinuing from the study will be 
summarized by [CONTACT_7169], treatment and overall. Reasons of premature discontinuation will 
also be summarized . 
8.4.2. Demographics and Other  Baseline Characteristics  
Patient  demographics and other baseline characteristics will be summarized  by [CONTACT_7169], 
treatment and overall using descriptive statistics.  
8.4.3. Prior and Concomitant Medications  
Prior and concomitant medications will be classified u sing the World Health Organization Drug 
dictionary, and summarized by [CONTACT_352531] (PT). 
8.4.4. Efficacy Analysis 
Efficacy analyses will be conducted for the FAS.  
[IP_ADDRESS]. Primary Efficacy Analysis 
The hypothesis for the primary efficacy analysis is that there is a positive treatment difference 
(CK-2127107 minus placebo) in change from baseline to Week [ADDRESS_438870] ( -5, -1, 3, 3) to reflect the assumed 
relationship for the placebo, 300 mg/day, 600 mg/day and 900 mg/day dose groups. The response variable in the model will be the change in the percent predicted SVC from baseline to 
each post -baseline visit. The model will include the terms of treatment, baseline value, pooled 
site, visit, randomization stratification factors of  riluzole use/non-use and stratified edaravone 
use/non-use , as well as treatment -by-visit and baseline- by-visit interactions. A n unstructured 
variance- covariance structure will be used to model the within -subject errors . 
[IP_ADDRESS]. Secondary Efficacy Analysis 
Slope from baseline in the mega -score of muscle strength will be analyzed using a MMRM. The 
response variable will be the change from baseline to each post- baseline visit. The model will 
include the terms of treatment, the baseline value, pooled site , time, randomization stratification 
factors of  riluzole use/non-use, and stratified edaravone use/non- use as well as treatment -by-
baseline and treatment -by-time interactions. A random slope effect will be assumed in the model. 
Change from baseline in the ALSFRS- R will be analyzed using the same method as for the 
primary  efficacy  analysis.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  48   [IP_ADDRESS]. Exploratory Efficacy Analysis 
Exploration of the dose-response relationship will come from model- based analys es that will use  
various assumptions of an implicit dose- response relationship. In addition, placebo will be tested 
against each dose group of CK-2127107 for specified endpoints and the 600 mg/day and 
900 mg/day dose groups combined.  
[IP_ADDRESS]. Multiplicity  
The global null hypothesis for the primary and secondary efficacy endpoints will be tested in a 
pre-specified order using a closed testing procedure. This procedure will maintain the family-
wise error rate at  two-sided significance level of 0.05 for all hypotheses tested in a confirmatory 
sense. Details of the procedures will be provided in the Statistical Analysis Plan . 
Hypotheses other than the primary and secondary efficacy endpoints will also be tested with a 
significance level of 0.05. However, no adjustments for multiple comparisons will be made for these tests . 
8.4.5. Safety Analysis 
Safety analyses will be conducted for the SAS. Safety data will be summarized by [CONTACT_7169], treatment and overall using descr iptive statistics.  
[IP_ADDRESS]. Study Drug Exposure  
The amount of study drug received and duration of study drug exposure will be summarized. 
[IP_ADDRESS]. Adverse Event  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
tabulated by [CONTACT_9313] (SOC) and PT. Individual events (PT) within each SOC will be presented in order of descending frequency. 
An AE (or SAE) will be regarded as treatment emergent if it starts or worsens (e.g., increases in 
severity or frequency) during or after the first  dose of study drug. TE AEs will be summarized by 
[CONTACT_764], and by [CONTACT_29978]. All AEs will be listed.  
[IP_ADDRESS]. Serious Adverse Event  
Treatment emergent SAEs will be summarized by [CONTACT_764], and by [CONTACT_29978]. All SAEs will be listed.  
[IP_ADDRESS]. Clinical Laboratory Parameters  
For each laboratory parameter, the number and percentage of subjects with alert values or values 
outside the normal range during the study will be tabulated. All laboratory evaluations identi fied 
as outside the normal range or as alerts by [CONTACT_352532]. The value and 
change from baseline in continuous laboratory parameters will be summarized at each scheduled 
visit where laboratory measurements are taken.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  49   [IP_ADDRESS]. Vital Signs  
For each measurement  of heart rate, blood pressure, respi[INVESTIGATOR_697], and BMI , the number and 
percentage of subjects with clinically relevant abnormalities during the study will be tabulated. 
All measurements identified as clinically relevant abnormalities will be listed. The value and 
change from baseline in heart rate, blood pressure, respi[INVESTIGATOR_352503].  
[IP_ADDRESS]. ECGs  
For each ECG measurement, the number and percentage of subjects with cli nically relevant 
abnormalities during the study will be tabulated. ECG measurements identified as clinically 
relevant abnormalities will be listed. The value and change from baseline in ECG measurements 
will be summarized at each scheduled visit where measurements are taken.  
[IP_ADDRESS]. Physical and Neurological Examinations 
The number and percentage of subjects deemed by [CONTACT_352533]. All measurements identified as clinically relevant 
abnormalities will be listed.  
[IP_ADDRESS]. Ashworth Score 
Ashworth score will be determined bilaterally at the elbows and knees with the results  
summarized at each body location.  
[IP_ADDRESS]. Falls Assess ments  
The number and percentage of subjects with falls will be tabulated at each scheduled visit where 
falls assessments are taken. Activities engaged at the time of the fall, physical symptoms 
experienced immediately preceding the fall, and if the fall result ed in injury will also be 
summarized.  
[IP_ADDRESS]. Beck Depression Inventory -Fast Screen  
The total score of the BDI -Fast Screen  is determined by [CONTACT_352534] 
[ADDRESS_438871] will be explor ed. 
Graphical and tabular presentation s will be provided as appropriate. 
8.4.7. Pharmacokinetic Analysis 
PK analyses will be conducted using the PKS.   All of the PK samples collected, including those 
obtained at Hour 3 on Day 1 as well as Hour 3 and Hour 6 at Week 2 and Week 12 from patients enrolled prior to Amendment 03, will be used for PK analyses. PK parameters  such as t
max, Cmax, 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  50   Ctrough, AUC 0-24, AUC ∞, CL/F, V/F, t ½ and R AC will be summarized by [CONTACT_352535].  Nominal sample times will be presented in all statistical and 
graphical summaries .   
The observed plasma concentrations of CK -2127107 and its metabolites (if applicable) and 
riluzole  at planned sampling time points will be summarized and liste d. The potential for drug -
drug interaction between CK-[ADDRESS_438872] patient completes dosing, an interim analysis may be conducted by [CONTACT_1034]. 
8.6. Statistical Software  
Statistical analyses will be performed using SAS® version 9.4 or greater.  
8.7. Changes in Statistical Methods  
All changes in statistical methods that are described in the statistical analysis plan will be 
documented in the clinical study report. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : [ADDRESS_438873] ( IRB)/Research E thics Board 
(REB) /Ethics Committee (EC)  and regulatory authorities, as applicable. 
9.2. Initiation Visit  
Prior to the start of the clinical study  at each site, the representative(s) of the Sponsor will meet 
with the Investigator(s) and appropriate clinical staff to familiarize the Investigator and clinical 
staff with the materials necessary for conducting the clinical study.  
9.3. Disclosure  
All information provided regarding the study, as well as all information collected/documented 
during the course of the study, will be regarded as confidential. The Investigator agrees not to disclose such information in any way without prior written permission from the Sponsor. 
Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, 
oral presentations, abstracts, etc.) by [CONTACT_737](s) or their representative(s), shall require 
prior notification and review, within a reasonable time frame, by [CONTACT_1034], and cannot be 
made in violation of the Sponsor’s confidentiality restrictions or to the detriment of the 
Sponsor’s intellectual property rights. 
9.4. Monitoring  
The Sponsor will designate site monitor s who will be responsible for monitoring this clinical 
trial. The site monitor will monitor the study conduct, proper eCRF and source documentation completion and retention, and accurate study drug accountability. To this end, the monitor will visit the study site  at suitable intervals and be in frequent contact [CONTACT_352536] . It is essential that the site monitor h ave access to all documents (related to the 
study and the individual participants) at any time these are requested. In turn, the site monitor will adhere to all requirements for patient  confidentiality as outlined in the ICF. The Investigator 
and other study personnel will be expected to cooperate with the site monitor, to be available during a portion of the monitoring visit to answer questions, and to provide any missing information. 
9.5. Institutional Review Board/Research Ethics Board/Ethics Committee   
In accordance with the US Code of Federal Regulations  (CFR) , [ADDRESS_438874] 
recruitment advertisement s (if applicable), and ICF will be submitted to the IRB /REB/EC  for 
review and subsequent written approval by [CONTACT_1201] /REB/EC  must be received  before 
proceeding . The Sponsor will supply relevant material for the Inve stigator to submit to the IRB  
for the protocol’s review and approval. Verification of the IRB/REB/EC  unconditional approval 
of the protocol and the written ICF statement will be transmitted to the Investigator.  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  52   The IRB /REB/EC  will be informed by [CONTACT_352537]. Approval for protocol am endments will be transmitted in writing 
to the Investigator. If requested, the Investigator will permit audits by [CONTACT_1201] /REB/EC  and 
regulatory inspections by [CONTACT_20618]/documents. 
The Inve stigator will provide the IRB /REB/EC  with progress reports at appropriate intervals (not 
to exceed one year) and a Study Progress Report following the completion, termination, or 
discontinuation of the Investigator’s participation in the study. 
9.6. Informed Consent  
Before protocol -specific procedur es are carried out, written informed consent for the study will 
be obtained from patients. The ICF generated by [CONTACT_737] (or designee) will be approved (along with the protocol) by [CONTACT_1201] /REB/EC  and will be acceptable to the Sponsor. 
The Investiga tor (or designee) will explain the nature of the study and the action of the test 
product. The patients will be informed that participation is voluntary and that patients can withdraw from the study at any time. In accordance with 21 CFR 50, informed consent shall be documented by [CONTACT_2224] a written ICF approved by [CONTACT_1201] /REB/EC  and will be signed by [CONTACT_352538]- specific procedures being performed . A copy of the signed consent, and 
the original will be maintained with the patient’s reco rds. A copy of the IRB /REB/EC  approved 
ICF must be sent to the Sponsor (or designee). 
9.7. Records  
The results from data collected during the study will be recorded in the patient ’s eCRF . To 
maintain confidentiality, the patient  will be identified only by a uni que identification number. 
The completed eCRFs will be transferred to the Sponsor or designee. All source documents, records, and reports will be retained by [CONTACT_352539] 21 CFR 312.62(c). All 
primary data, or copi[INVESTIGATOR_20583] (e.g., laboratory records, source documents, correspondence, photographs, and computer records), which are a result of the original observations and activities of the study and are necessary for the reconstruction and evaluation of any study report, will be 
retained  in the study site  archives.  
9.8. Reference to Good Clinical Practices (GCP)  
The study procedures outlined in this protocol will be conducted in accordance with the CFR 
governing Protection of Human Subjects (21 CFR 50), Financial Disclosure by [CONTACT_352540] (21 CFR 54), IRBs (21 CFR 56), Investigational New Drug Application 
(21 CFR  312), and Applications for FDA Approval to Market a New Drug (21 CFR 314), as 
appropriate. As such, these sections of U.S. Title 21 CFR, along with the applicable ICH Guidelines, are commonly known as Good Clinical Practices (GCP). 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  53   10. REFERENCES  
Brooks, B. R., R. G. Miller, et al. (2000). "El Escorial revisited: revised criteria for the diagnosis 
of amyotrophic lateral sclerosis." Amyotroph Lateral Scler Other Motor Neuron Disord 
1(5): 293-299. 
CTCAE. "Common Terminology Criteria for Adverse Events (CTCAE) v4.0." from 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40. 
Ducharme, M. P., M. Smythe, et al. (1993). "Drug-induced alterations in serum creatinine 
concentrations." Ann Pharmacother 27 (5): 622-633. 
FDA (2009). Guidance for Industry, Drug- induced liver injury: Premarketing clinical evaluation. 
D. Safety.  
Inker, L. A., C. H. Schmid, et al. (2012). "Estimating glomerular filtration rate from serum 
creatinine and cystatin C." N Engl J Med  367(1): 20 -29. 
Kiernan, M., S. Vucic, et al. (2011). "Amyotrophic lateral sclerosis." Lancet  377(9769): 942-
955. 
Lacomblez, L., G. B ensimon, et al. (1996). "Dose-ranging study of riluzole in amyotrophic 
lateral sclerosis." The Lancet  347: 1425-1431. 
Temple, R. (2006). "Hy's law: predicting serious hepatotoxicity." Pharmacoepi[INVESTIGATOR_9697]. 
15(4): 213-220. 
Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. (2017). "Safety and 
efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a 
randomised, double-blind, placebo- controlled trial." Lancet Neurol  16(7): 505-512. 
 
 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  54   APPENDIX A. SCHEDULE  OF EVENTS  
Study Procedures  Screening  Day 1 Week 2  Week 4  Week 8  Week 12  FU Visit  
Informed Consent  X       
Incl/Excl Criteria  X       
Demographics  X       
Medical History  X       
Concomitant Meds  X X X X X X X 
Physical Exa ma X      X 
Neurological Exam  X      X 
Height   X       
Weight  & BMI  X X X X X X X 
12-Lead ECG  X   X   X 
Vital Signs  Xb X X X X X X 
Clinical Safety Labsc X X X X  X X 
Pregnancy Testd X      X 
PK Samplee  X X X X X  
SVC  X X X X X X X 
Muscle Strength  X X X X X X X 
ALSFRS -R X X X X X X X 
Voice recording X X X X X X X 
Fine Motor Skillsf X X X X X X X 
ALSAQ -5 X X X X X X X 
Health Economic 
Outcomes Measurements   X X X X X X 
Ashworth Scale  X X X X X X X 
Falls Assessments   X X X X X X 
Study Drug Dosing   X X X X X  
AE/SAE Evaluations   X X X X X X 
BDI-Fast Screen  X X X X X X X 
a Complete physical examination at Screening Visit, abbreviated physical examination at FU visit  
b Temperature only at Screening  
c TSH only at Screening and Follow -Up Visit  
d Serum pregnancy test only for females of childbearing potential  
e PK sampling on Day 1 visit, Week 2 visit, Week 4 visit, Week 8 visit, and Week 12 visit; refer to Table  3 in 
protocol   
f If the device is suitable for use in that region  
 
Schedule of Events for Home Testing  
SVC * To be done every Saturday (± 1 day) independent of day of first dose  
Voice recording  To be done every Saturday (± 1 day) independent of day of first dose  
     *if the device is suitable  for use in that region  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  55   APPENDIX B.  MEDICATIONS AND FOODS THAT INHIBIT OR INDUCE CYP3A4 
OR ARE OCT1/OCT2 SUBSTRATES  
CYP3A4 Inhibitors  CYP3A4 Inducers  
Strong Inhibitors:  (Avoid)  Strong Inducers : (Avoid)  
indinavir  avasimibe  
nelfinavir  carbamazepi[INVESTIGATOR_352504]. John’s Wort  
nefazodone  rifampin  
ketoconazole  rifabutin  
grapefruit   
Seville oranges   
  
Moderate Inhibitors:  Moderate Inducers:  
erythromycin  bosentan  
diltiazem  efavirenz  
verapamil  etravirine  
suboxone  modafinil  
 nafcillin  
 nevirapi[INVESTIGATOR_352505]:  Weak Inducers:  
cimetidine  amprenavir  
 aprepi[INVESTIGATOR_352506]1 Substrates (Avoid)  OCT2 Substrates (Avoid)  
oxaliplatin  pi[INVESTIGATOR_352507]1 Substrates (Use with Caution)  OCT2 Substrates (Use with Caution)  
aciclovir  metformin  
ganciclovir   
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  56   APPENDIX C. LIVER SAFETY MONITORING AND ASSESSMENT  
Any patient  enrolled in a clinical study with active drug therapy who  reveals an increase of 
serum aminotransferase (AT) to > [ADDRESS_438875] or bilirubin > 2 × ULN, should undergo detailed 
testing for liver enzymes (including at least ALT, AST , alkaline phosphatase [ ALP ], and TBL). 
Testing  should be repeated within 48-[ADDRESS_438876] any symptoms suggestive of hepatobiliary dysfunction. 
Definition of L iver A bnormalities  
Confirmed abnormalities will be characterized as moderate and severe as follows: 
  ALT or AST   Total Bilirubin  
Moderate   > 3× ULN  or > 2× ULN  
Severe   > 3× ULN  and > 2× ULN  
In addition, the patient  should be considered to have severe hepatic abnormalities for any of the 
following: 
• ALT or AST  > 8× ULN  
• ALT or AST  > 5× ULN for more than 2 weeks   
• ALT or AST  > 3× ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophi lia (> 5%)  
The investigator may determine that abnormal LFTs , other than as described above, may qualify 
as moderate or severe abnormalities and require additional monitoring and follow-up. 
Follow- up Procedures  
Confirmed moderate and severe abnormalities in hepatic functions should be thoroughly 
characterized by [CONTACT_317257], detailed pertinent history, physical 
examination and laboratory tests. Patient s with confirmed abnormal LFTs  should be followed as 
described below.  
Confirmed moderately abnormal LFTs should be repeated 2- 3 times weekly then weekly or less 
if abnormalities stabilize or the study drug has been discontinued and the patient is 
asymptomatic . 
Severe hepat ic liver function abnormalities as defined above, in the absence of another etiology, 
may be  considered an important medical event and may be reported as a SAE . The S ponsor 
should be contact[CONTACT_352541] s for whom severe hepatic liver function 
abnormalities possibly attributable to study drug are observed. 
To further assess abnormal hepatic laboratory findings, the investigator is expected to: 
• Obtain a more detailed history of symptoms and prior or concurrent diseases. 
Symptoms and new onset- diseases sho uld be recorded as ‘adverse events ’ on the AE 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  57   page of the eCRF. Illnesses and conditions such as hypotensive events, and 
decompensated cardiac disease t hat may lead to secondary liver abnormalities should 
be noted. Non -alcoholic steatohepatitis is seen in obese hyperlipoproteinemic, and/or 
diabetic patients and may be associated with fluctuating aminotransferase levels . The 
investigator should ensure that the medical history form captures any illness that pre-
dates study enrollment that may be relevant in a ssessing hepatic function . 
• Obtain a history of concomitant drug use (including non-prescription medication, complementary and alternative medications), alcohol use, recreational drug use, and 
special diets . Medications, including dose, should be entered on the concomitant 
medicat ion page of the eCRF . 
• Obtain a history of exposure to environmental chemical agents. 
• Based on the patient ’s history, other testing may be appropriate including:  
− acute viral hepatitis (A,  B, C, D, E or other infectious agents)  
− ultrasound or other imaging to assess biliary tract disease 
− other laboratory tests including i nternational normalized ratio  (INR), direct 
bilirubin  
• Consider gastroenterology or hepatology consultations 
Patient  Discontinuation 
In the absence of an explanation for increased LFTs, such as viral hepatitis, pre- existing or acute 
liver disease or exposure to other agents associated with liver injury, the patient may be discontinued from the study. The investigator may determine that it is not in the patient ’s best 
interest to continue study enrollment. Discontinuation of treatment should be considered  if: 
• ALT or AST > 8  × ULN  
• ALT or AST > 5  × ULN for more than 2 weeks  
• ALT or AST > 3 × ULN and TBL > 2 × ULN  
• ALT or AST > 3  × ULN  with th e appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophi lia (> 5%)   
In addition, if close monitoring for a patient  with moderate or severe hepatic laboratory tests is 
not possible, drug should be discontinued. 
Hy’s Law Definition  - Drug -induced jaundice caused by [CONTACT_77813], without a 
significant obstructive component, has a high rate of bad outcomes, from 10–50% mortality (or 
transplant) ( Temple 2006 ; FDA 2009). 
The three “requirements” for Hy’s Law are:   
1. Patients with  ALT or AST ≥ 3 × ULN compared to placebo, AND  
2. For patients with AT elevations (often much greater than 3 × ULN), elevation of serum 
TBL > 2 × ULN, without initial findings of c holestasis (elevated serum ALP), AND  
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  58   3. No other reasons can be found to explain the combination of increased AT and TBL, such 
as viral hepatitis A, B, or C; preexisting or acute liver disease; or another drug capable of 
causing the observed injury. 
CONFIDENTIAL   Protocol CY 5022 
CY 5022 Protocol Amendment 03 : 18 Apr 2018  59   APPENDIX D. CLINICAL LABORATORY EVALUATIONS  
All Visits:  
TBL Urea nitrogen  Globulin Magnesium  
Direct bilirubin  Creatinine  Triglycerides  Cystatin C  
Indirect bilirubin  Glucose Cholesterol UA 
ALP  Uric acid  Creatine kinase  CBC with 
differential  ALT  Calcium  Sodium 
AST  Phosphorus Potassium eGFR (calculated 
by [CONTACT_9289] -EPI 
[INVESTIGATOR_352508] C 
equation) Gamma -glutamyl 
transferase  Total protein  Bicarbonate 
Lactate 
dehydrogenase  Albumin  Chloride 
Screening and Follow-Up only: 
TSH  
Serum Beta Human Chorionic Gonadotropin 
 